As of 2025-07-02, the Relative Valuation of Kymera Therapeutics Inc (KYMR) is (77.96) USD. This relative valuation is based on P/E multiples. With the latest stock price at 44.44 USD, the upside of Kymera Therapeutics Inc based on Relative Valuation is -275.4%.
The range of the Relative Valuation is (62.96) - (87.30) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.5x - 23.6x | 19.6x |
| Forward P/E multiples | 17.0x - 28.2x | 22.6x |
| Fair Price | (62.96) - (87.30) | (77.96) |
| Upside | -241.7% - -296.4% | -275.4% |
| Date | P/E |
| 2025-06-26 | -12.36 |
| 2025-06-25 | -12.56 |
| 2025-06-24 | -12.74 |
| 2025-06-23 | -12.51 |
| 2025-06-20 | -12.40 |
| 2025-06-18 | -12.55 |
| 2025-06-17 | -12.53 |
| 2025-06-16 | -12.66 |
| 2025-06-13 | -12.70 |
| 2025-06-12 | -12.78 |
| 2025-06-11 | -13.08 |
| 2025-06-10 | -13.14 |
| 2025-06-09 | -12.75 |
| 2025-06-06 | -12.87 |
| 2025-06-05 | -12.88 |
| 2025-06-04 | -11.97 |
| 2025-06-03 | -11.78 |
| 2025-06-02 | -11.66 |
| 2025-05-30 | -8.01 |
| 2025-05-29 | -8.18 |
| 2025-05-28 | -7.79 |
| 2025-05-27 | -7.61 |
| 2025-05-23 | -7.97 |
| 2025-05-22 | -8.16 |
| 2025-05-21 | -8.15 |
| 2025-05-20 | -8.50 |
| 2025-05-19 | -8.16 |
| 2025-05-16 | -8.18 |
| 2025-05-15 | -8.12 |
| 2025-05-14 | -8.04 |
| 2025-05-13 | -8.42 |
| 2025-05-12 | -8.70 |
| 2025-05-09 | -8.13 |
| 2025-05-08 | -8.32 |
| 2025-05-07 | -7.87 |
| 2025-05-06 | -7.72 |
| 2025-05-05 | -9.08 |
| 2025-05-02 | -9.54 |
| 2025-05-01 | -9.34 |
| 2025-04-30 | -9.26 |
| 2025-04-29 | -9.11 |
| 2025-04-28 | -9.09 |
| 2025-04-25 | -8.99 |
| 2025-04-24 | -9.07 |
| 2025-04-23 | -8.30 |
| 2025-04-22 | -7.79 |
| 2025-04-21 | -7.34 |
| 2025-04-17 | -7.02 |
| 2025-04-16 | -6.76 |
| 2025-04-15 | -6.88 |